Table 6 Resistance of gram positive cocci to various antimicrobials
From: Emerging antimicrobial resistance in early and late-onset neonatal sepsis
Organism (number) | Ampicillin-sulbactam | Amikacin | Cefotaxime | Ceftazidime | Imipenem | Vancomycin | Ciprofloxacin | Clindamycin | Polymyxin | Rifampicin | Piperacillin-tazobactam |
CONS (33) | 33(100%) | 16(48.5%) | 31(93.9%) | 31(93.9%) | 28(84.8%) | 8(24.2%) | 25(75.8%) | 18(55%) | ND | 15(46%) | 33(100%) |
MRSA (9) | 9(100%) | 3(33.3%) | 9(100%) | 9(100%) | 8(88.9%) | 0 | 8(88.9%) | 3(33%) | ND | 3(33%) | 9(100%) |
B streptococcus (4) | 4(100%) | 2(50%) | 3(75%) | 3(75%) | 2(50%) | 1(25%) | 3(75%) | 3(75%) | ND | 4(100%) | 4(100%) |
St. pneumonie (1) | 1(100%) | 1(100%) | 1(100%) | 1(100%) | 1(100%) | 0 | 0 | 1(100%) | ND | 1(100%) | 1(100%) |
Staph aureus (4) | 4(100%) | 3(75%) | 4(100%) | 4(100%) | 4(100%) | 0 | 3(75%) | 2(50%) | ND | 2(50%) | 4(100%) |
| Â | Gentamicin | Meropenem | Cefoperazone | Cefepime | Amoxicillin-clavulanate | Ceftriaxone | Cotrimoxazole | Erythromycin | Cefoxitin | Levofloxacin | Cefuroxime |
CONS (33) | 18(55%) | 28(85%) | 33(100%) | 29(88%) | 26(79%) | 33(100%) | 27(82%) | 28(85%) | 25(76%) | 22(67%) | 33(100%) |
MRSA (9) | 7(77.8%) | 9(100%) | 9(100%) | 9(100%) | 9(100%) | 9(100%) | 8(89%) | 7(78%) | 9(100%) | 7(78%) | 9(100%) |
B streptococcus (4) | 0 | 2(50%) | 4(100%) | 2(50%) | 3(75%) | 4(100%) | 4(100%) | 4(100%) | 3(75%) | 4(100%) | 4(100%) |
St. pneumonie (1) | 0 | 1(100%) | 1(100%) | 0 | 0 | 1(100%) | 1(100%) | 1(100%) | 1(100%) | 1(100%) | 1(100%) |
Staph aureus (4) | 4(100%) | 4(100%) | 4(100%) | 4(100%) | 0 | 4(100%) | 4(100%) | 4(100%) | 3(75%) | 4(100%) | 4(100%) |